Fremanezumab for preventing migraine

2nd September 2020 by Dr Louise Hudman

Fremanezumab for preventing migraine

This is a new guideline from NICE advising that we can use fremanezumab for preventing migraine in selected populations. It was published in June 2020.

It can be used if:

  • the migraine is chronic ie 15 or more headache days each month for at least 3 months, with at least 8 of those days having features of migraine AND
  • at least three preventative drugs have failed AND
  • it is provided according to the commercial agreements with the company.

It should be stopped if it does not reduce migraine frequency by 30% after 12 weeks of treatment.

Read more

No credit card details needed – it takes two minutes.

Join free trial


Already a member? Login to view this content.


"I have decided to retire from medicine, and so from the NASGP too. You have my heartfelt thanks for being around, especially for all the useful articles in your journal, and I wish you well for the future. "

Dr Stephen Pope

See the full list of features within our NASGP membership plans